NTC, an international pharmaceutical company headquartered in Milan, Italy, and Stada, a global leading pharmaceutical player with significant presence in the Middle East and North Africa (Mena) region, have announced a commercial ophthalmic partnership. 

 

NTC is granting to Stada licence and distribution rights for certain proprietary ophthalmic products in the region, intended to address several ophthalmic diseases, in particular blepharitis, dry eye and allergy.

 

“We are excited to partner with a leading company like Stada,” – says Riccardo Carbucicchio, President and CEO of NTC – “for some of our innovative treatments in ophthalmology. The products included in the agreement with Stada leverage technologies aimed at simplifying the therapeutic care of patients in treating dry eye, allergy, and blepharitis, and thus favoring compliance. An agreement with a global player like Stada is a great opportunity for our vision at NTC and we are confident that our ophthalmic products will reach a broad range of patients in the Mena region.”

 

“By combining NTC’s ophthalmology expertise with Stada’s deep sales and marketing footprint in the Mena region, we look forward to offering patients and healthcare professionals an attractive range of options for care for eye health,” commented Carsten Cron, Stada’s Head of Emerging Markets. 

 

“The ophthalmic products will further strengthen Stada’s Specialty pipeline in the region that was recently reinforced through partnerships for oncology, allergy and anaesthetic medicines.”

 

NTC is running a large international research and development programme in ophthalmology, engaging many researchers and clinical centres, focusing on developing novel therapeutic solutions to offer relief for still unmet needs to the medical community and the patients.-- TradeArabia News Service